AML,ALL,MDS
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with acute leukemia or myelodysplastic syndrome 2.The first time of allogeneic HSCT (no limitation of stem cell source, or HLA disparity) 3.20-y.o or older 4.No limitation of conditioning regimen, GVHD prophylaxis and supportive therapy
Exclusion criteria
Exclusion criteria: 1.Past history of allogeneic HSCT 2.Without written informed concent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection during 100 days after HSCT (pathogens, organs and cumulative incidence) | — |
Secondary
| Measure | Time frame |
|---|---|
| Day 100 nonrelapse mortality 1-y nonrelapse mortality 1-y overall survival | — |
Countries
Japan
Contacts
Kanto Study Group for Cell Therapy Trial Office